Adiponectin

What is Adiponectin?

Adiponectin is a hormone released by fat cells that helps your body use insulin and manage blood sugar and fat storage.

Adiponectin is a 244-amino-acid protein hormone made almost entirely by adipocytes, the fat-storing cells in white adipose tissue, with smaller amounts coming from skeletal muscle, heart muscle, and the cells lining blood vessels. It circulates in low-, medium-, and high-molecular-weight forms, and the high-molecular-weight form does most of the metabolic work (StatPearls/NCBI Bookshelf, 2023). What makes it unusual among hormones made by fat tissue: as body fat goes up, adiponectin goes down, not up. Leptin and most other adipokines rise with fat mass. Adiponectin runs the opposite direction, and weight loss tends to raise it back (Cleveland Clinic, 2025; StatPearls, 2023). It binds two receptors, AdipoR1, found mostly in muscle, and AdipoR2, found mostly in liver, and switches on a pathway called AMPK that increases glucose uptake and fat burning. A second pathway, through PPAR-alpha, improves insulin sensitivity and calms inflammation in blood vessel walls, muscle, and immune cells (StatPearls, 2023). In population research, lower levels are associated with obesity, insulin resistance, type 2 diabetes, gestational diabetes, and atherosclerosis. A doctor ordering this test is usually working through one of those questions, not screening a healthy person at random (Cleveland Clinic, 2025; Labcorp, 2026). Very high levels turn up in the literature in severe underweight, including anorexia nervosa, consistent with adiponectin's role as fat tissue's own signal about how much of it is actually there.

Typical reference context

There's no single universal clinical cutoff for adiponectin the way there is for, say, fasting glucose. Two major US reference sources stratify it two different ways, by body composition or by age, and the numbers don't line up neatly between them. That's normal for this marker, not an error in either source, and it's a reason to read your result against the specific range your own lab printed, not a number from a different lab's chart.

What changed recently

A 17-year Korean cohort study of 35,026 people, published in the Diabetes & Metabolism Journal on September 8, 2025, found that people in the lowest adiponectin group had 3.20 times the adjusted risk of developing MASLD (metabolic dysfunction-associated steatotic liver disease, the condition renamed from NAFLD in 2023) compared with the highest group, with the risk rising step by step across the lower quintiles and a stronger association in women. It's one of the largest and longest-running datasets on this specific marker to date.

A separate 2024 study in Cardiovascular Research adds an important caution to the so-called "adiponectin paradox," where some studies find higher adiponectin linked to worse heart failure and atrial fibrillation outcomes, the opposite of what its anti-inflammatory reputation would predict. Using Mendelian randomization across more than a million genetic records, the researchers found that while the observational link was real, the genetic evidence did not support adiponectin actually causing those outcomes. The likely explanation is that sicker hearts drive adiponectin up, not the other way around, a reminder that an observed association and a causal one are not the same thing.

Tests often checked alongside this

• Fasting glucose or HbA1c — because adiponectin tracks insulin sensitivity, so a direct glucose measure fills in the other half of the insulin-resistance picture.
• Leptin — since researchers use the leptin-to-adiponectin ratio as a single metabolic-syndrome marker precisely because the two hormones move in opposite directions with fat mass (International Journal of Obesity, 2024).
• Lipid panel — particularly triglycerides and HDL, because adiponectin's effect on insulin sensitivity is closely tied to how the body handles fat in the blood.
• High-sensitivity CRP — given adiponectin's anti-inflammatory role, to get a general inflammation reading alongside it.
• Liver enzymes or a MASLD workup — given the 2025 cohort finding linking low adiponectin to fatty liver risk.

What can affect this marker

• Visceral fat specifically suppresses adiponectin production more than subcutaneous fat does, which is part of why waist circumference tracks with lower readings even at a similar overall weight.
• Recent weight change, since levels rise after weight loss and fall with weight gain, tracking adipocyte size rather than body weight on its own (StatPearls, 2023).
• Sex, since women tend to run higher than men at a comparable BMI, which is why Cleveland Clinic's reference ranges are split by sex rather than given as one number.
• The assay method and the patient's age band, since Labcorp's own reference intervals shift from 2.3-26.5 ug/mL under age 8 to 3.0-21.1 ug/mL over 60, reflecting both biology and the specific test method.
• Genetic variation, since Mendelian randomization research shows a real heritable component to circulating adiponectin that's independent of how much body fat someone carries (Cardiovascular Research, 2024).

What to track over time

• Your adiponectin result next to your weight and waist measurement at each visit.
• Which reference range your lab used, since it varies by age, sex, or BMI stratification.
• Related labs drawn the same day, such as glucose, HbA1c, and a lipid panel, so the full metabolic picture stays together.
• Whether a new result was flagged against the same kind of range as your last one, so you're comparing like with like.

What to ask your doctor

• What reference range did the lab use for my result, and is it based on my age, sex, or BMI?
• Does this number change how you're thinking about my metabolic or cardiovascular risk?
• Should this be repeated, and on what timeline?
• How does this result fit with my glucose and lipid numbers from the same visit?
• Was there a specific reason you ordered adiponectin rather than a more routine test?

This glossary entry is for informational purposes only and is not a substitute for professional medical advice. Read our Terms of Use.

Frequently asked questions